Tracey Gaspari leads the IRAP Pharmacology Lab and holds a continuing teaching and research appointment in Dept of Pharmacology, Monash University. She is internationally recognised as a cardiovascular pharmacologist in the field of RAS biology/pathophysiology. Tracey pioneered the novel concept of targeting the enzyme, Insulin Regulated Aminopeptidase (IRAP) in cardiovascular disease, with a focus on fibrotic and vascular diseases. Her ground breaking work resulted in granting of a method of use patent (>5 countries, incl US) on IRAP inhibitors in fibrotic diseases. She is a co-founder of the spinout company, Inosi Therapeutics, backed by investment from IP Group and Monash Investment Holdings. Inosi Therapeutics is focused on the development of first-in-class, orally active IRAP inhibitors to treat difficult-to-reverse fibrosis. In collaboration with Inosi and the other co-founders, Tracey led the team that was successful in receiving an MRFF Targeted Translation Research Accelerator (TTRA) grant to develop IRAP inhibitors to treat diabetes-induced renal and cardiovascular disease. Her research continues to explore ways in which targeting IRAP can be beneficial in multiple inflammatory and fibrotic diseases.

Laboratory Head in Cardiovascular Pharmacology at Monash Institute of Pharmaceutical Sciences, Monash University, National Heart Foundation Future Fellow and Monash Talent Accelerator Fellow. MRFF REDI Industry Fellow Alumni and Baker Fellow Alumni. Dr Qin also plays an integral role on the Board of Directors of the Australasian Pharmacologists and Toxicology Society, the Global Academic Drug Discovery Consortium, and Co-lead MIPS Cardiometabolic Therapeutic Area. Dr Qin is an emerging leader in translational pharmacology, driven by a visionary pursuit to develop "pro-resolving medicines" for treating cardiopulmonary diseases, one of the leading causes of death globally. She has published >70 peer-reviewed papers in top journals such as Nature Communications, Circulation, Cardiovascular Research, and the British Journal of Pharmacology. She has secured $9M in competition funding including the Australian National Health and Medical Research Council, National Heart Foundation, Diabetes Australia etc. Her outstanding leadership and scholarly achievements have been recognized through the receipt of >20 prestigious awards, including the Hypertension Australia Mid-Career Award (2023), Future Research Leader (2020), and the Asian Australian Leadership Award (2019), Cardiac Society Ralph Reader (2016). For more information, please visit: https://www.monash.edu/mips/themes/drug-discovery-biology/labs/cardiovascular-pharmacology.

Dr O'Donnell is an NHMRC Early Career Research Fellow in the Hypertension Laboratory, Monash University, with A/Prof Francine Marques. She completed her PhD at WEHI, Melbourne, and post-doctoral studies at the University of Massachusetts Medical School, Boston, where she studied the interplay between cell death, immune cell activation and autoimmune disease. Her research focuses on understanding the interplay between the gut microbiome and the immune system during cardiovascular disease.